[1] Homey B, Assmann T, Vohr HW, et al. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol, 1998, 160:5331-5340.
[2] Panhans-Gross A, Novak N, Kraft S, et al. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol, 2001,107:345-352.
[3] Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional altera tions of epidermal antigen-presenting dendritic cells in atopic dermatitis.J Allergy Clin Immunol, 2001,107:519-525.
[4] Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med, 1997,337:816-821.
[5] Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients:Part Ⅰ, efficacy. J Am Acad Dermatol, 2001,44:S28-38.
[6] Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol, 1998,102:637-644.
[7] Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol, 2001,44:S47-57.
[8] Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol, 2001,44:S58-64.
[9] Kawakami T, Soma Y, Morita E, et al. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology, 2001,203:32-37.
[10] Mayer K, Reinhard T, Reis A, et al.FK506 ointment 0.1 %-A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients.Klin Monatsbl Augenheilkd, 2001,218:733-736.
[11] Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol, 2001,44:S65-72.
[12] Vente C, Reich K, Rupprecht R, et al. Erosive mucosal lichen planus:response to topical treatment with tacrolimus. Br J Dermatol, 1999,140:338-342.
[13] Kaliakatsou F, Hodgson TA, Lewsey JD, et al. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol, 2002,46:35-41.
[14] Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea:a preliminary report. J Am Acad Dermatol, 2001, 44:995-998.
[15] Reich K, Vente C, Neumann C.Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol, 1998, 139:755-757.
[16] Petering H, Kiehl P, Breuer C, et al. Pyoderma gangraenosum:successful topical therapy with tacrolimus (FK506). Hautarzt, 2001,52:47-50.
[17] Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol, 1998,134:1101-1102.
[18] Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol, 1999, 141:103-107.
[19] Schnopp C, Remling R, Mohrenschlager M, et al. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema:a randomized, observer-blinded trial. J Am Acad Dermatol, 2002,46:73-77.
[20] Sugiura H, Uehara M, Hoshino N, et al. Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis. Arch Dermatol, 2000,136:1062-1063.
[21] Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease:a case series of 18 patients. Arch Dermatol, 2001,137:1202-1206.
[22] Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol, 2002,147:154-156.
[23] Bekersky I, Fitzsimmons W, Tanase A, et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol, 2001,44:S17-27.
[24] Duncan JI. Dfferential inhibitionof cutaneous T-cell-mediated reaction and epidermal cell proliferation by cytclosporin A,FK506, and rapamycin. J Invest Dermatol, 1994,102:84-88.
[25] Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment dose not affect collagen synthesis:result of a single-center randomized trial. J Invest Dermatol, 1998,111:396-398. |
